This intensive course is intended for scientists working in the field, and the presentations will be given by senior scientists from industry and academia. The number of participants is limited to 35, to allow in depth discussion. Should the number of applications exceed the maximum, preference will be given to applicants from EFMC adhering countries and employees of EFMC corporate members. Upon special request to the organisers, only based on financial conditions and supported by an argued recommendation of the head of the department of the applicant, up to 3 applicants from academia may be admitted at a reduced fee.
In the last ten years there have been significant developments in the field of designing small molecule protein degraders both as chemical tools and clinical candidates. These degraders can offer major advantages over small molecule inhibitors as a therapeutic strategy by achieving more complete target inhibition and by expanding the potentially druggable proteome. This course aims to provide opportunities for in depth discussions on the key aspects of PROTAC design and development for medicinal chemists. The course will introduce small molecule protein degraders, including PROTACs and molecular glues, and give a detailed overview of the novel technologies used to characterise protein degradation biophysically and in living cells. The course will finish with a series of medicinal chemistry case studies, including the discovery of clinical small molecule protein degraders.
Alessio CIULLI (University of Dundee, United Kingdom)
Suzanne O'CONNOR (University of Dundee, United Kingdom)
Laura HEITMAN (University of Leiden, The Netherlands)